<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402817</url>
  </required_header>
  <id_info>
    <org_study_id>1104-07</org_study_id>
    <nct_id>NCT01402817</nct_id>
  </id_info>
  <brief_title>Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas</brief_title>
  <official_title>A Pilot Study of Sutent®/Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor in Subjects With NF-1 Plexiform Neurofibromas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine if adults and children with neurofibromatosis type 1 who&#xD;
      have plexiform tumors given Sutent® respond to this drug therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label pilot study to evaluate the efficacy of Sutent® in individuals with NF1&#xD;
      who have clinically significant plexiform tumors. A secondary goal of this study will be to&#xD;
      seek to improve on current and novel tools to evaluate tumor response of plexiform tumors.&#xD;
      The rationale for this study arises from the response of human and murine NF1 cells to&#xD;
      Sutent® in vitro and the clinical response of individuals with NF1 using a similar&#xD;
      drug,Gleevec®. Following enrollment adult subjects will start receiving Sutent® by month at&#xD;
      25mg once a day for 28 days. Subjects will then have 14 days without taking any Sutent®. If&#xD;
      tolerated the dose will be increased to 37.5mg and 50mg with the same regimen (28 days of&#xD;
      taking medication followed by 14 without). Children will be started on a dose of 10mg/m2/day&#xD;
      once a day for 28 days. They will then have 14 days without taking any Sutent®. If tolerated&#xD;
      the dose will be increased to 15mg/m2/day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    1 patient died of uncertain cause but possibly related to drug.&#xD;
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">February 14, 2018</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Response</measure>
    <time_frame>6 months</time_frame>
    <description>To estimate the disease control rate (SD, PR, CR) with Sutent® in patients with neurofibromas (NF1). Tumor response criteria are determined by changes in size using all 3 dimensional measurements: width (W), transvers (T) , and length (L) measurements. Partial Response: ≥20% decrease in the sum of the products of the three perpendicular diameters of all target lesions (up to 5), taking as reference the initial baseline measurements.Stable Disease (SD): Neither sufficient decrease in the sum of the products of the three perpendicular diameters of all target lesions to qualify for PR (taking as reference the initial baseline measurements), nor sufficient increase in a single target lesions to qualify for PD, (taking as reference the smallest disease measurement since the treatment started).Progressive Disease (PD): 40% or more increase in the product of perpendicular diameters of ANY target lesion, taking as reference the smallest product observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volumetric Disease Evaluation</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the response rate with Sutent® in patients with plexiform neurofibromas using volumetric analysis of MRI scans</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Neurofibromatosis</condition>
  <condition>NF1</condition>
  <condition>Plexiform Neurofibromas</condition>
  <arm_group>
    <arm_group_label>Sutent®/Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upon enrollment, subjects will receive Sutent® orally. Adults (Age &gt;18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sutent®/Sunitinib</intervention_name>
    <description>Upon enrollment, subjects will receive Sutent® orally. Adults (Age &gt;18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.</description>
    <arm_group_label>Sutent®/Sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: patients must be ≥3 years of age and ≤65 years of age at the time of study entry&#xD;
&#xD;
          2. Diagnosis: Patients must meet clinical diagnostic criteria of neurofibromatosis type 1&#xD;
             (NF1). Patients must have clinically significant plexiform neurofibromas (biopsy&#xD;
             proven if possible with tissue blocks available). Clinically significant tumors are&#xD;
             those which are potentially life threatening or are impinging on vital structures or&#xD;
             significantly impair the quality of life from pain or other symptoms.&#xD;
&#xD;
          3. Disease status: Patients must have measurable disease.&#xD;
&#xD;
          4. Performance Level: Karnofsky ≥50 for patients &gt;10 years of age and Lansky ≥50 for&#xD;
             patients ≤10 years of age. Patients who are unable to walk because of paralysis, but&#xD;
             who are up in a wheelchair, will be considered ambulatory for the purpose of assessing&#xD;
             the performance score.&#xD;
&#xD;
          5. Prior therapy: Patients must have fully recovered from the acute toxic effects of all&#xD;
             prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.&#xD;
&#xD;
               1. Myelosuppressive chemotherapy: Must not have received within 3 weeks of entry&#xD;
                  onto this study.&#xD;
&#xD;
               2. Hematopoietic growth factors: At least 14 days since completion of therapy with a&#xD;
                  growth factor.&#xD;
&#xD;
               3. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy&#xD;
                  with a biologic agent. For agents that have known adverse events occurring beyond&#xD;
                  7 days after administration, the period must be extended beyond the time during&#xD;
                  which adverse events are known to occur. The duration of this interval must be&#xD;
                  discussed with the principal investigator.&#xD;
&#xD;
               4. XRT: ≥2 weeks for local palliative XRT (small port); ≥6 months must have elapsed&#xD;
                  if ≥50% radiation of pelvis; ≥6 weeks must have elapsed if other substantial BM&#xD;
                  radiation.&#xD;
&#xD;
          6. Organ function requirements&#xD;
&#xD;
             a. Adequate bone marrow function defined as i. Peripheral absolute neutrophil count&#xD;
             (ANC) ≥1000/µL ii. Platelet count ≥100,000/ µL(transfusion independent, iii.&#xD;
             Hemoglobin ≥8.0 gm/dL(may receive RBC transfusions) b. Adequate renal function defined&#xD;
             as i. Creatinine clearance or radioisotope GFR ≥70 mL/min/1.73 m2 or ii. A serum&#xD;
             creatinine based on age/gender as follows (Maximum Serum Creatinine (mg/dL)): Males: 6&#xD;
             to &lt;10 years:1; 10 to &lt;13 years: 1.2; 13 to &lt;16 years: 1.5; &gt;16 years 1.7. Females: 6&#xD;
             to &lt;10 years:1; 10 to &lt;13 years 1.2; 13 to &lt;16 years: 1.4; &gt;16 years: 1.4.&#xD;
&#xD;
             The threshold creatinine values above were derived from the Schwartz formula for&#xD;
             estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and&#xD;
             stature data published by the CDC.&#xD;
&#xD;
             c. Adequate Liver Function Defined As: i. Total bilirubin (sum of&#xD;
             conjugated+unconjugated)≤1.5 times upper limit of normal (ULN) for age, and ii.&#xD;
             SGPT(ALT)&lt;2.5 upper limit of normal ULN). For the purpose of this study, the ULN for&#xD;
             SGPT is 45 U/L iii. Serum albumin ≥2 g/dL d. Adequate cardiac function defined as: i.&#xD;
             Shortening fraction or ejection fraction greater than the LLN (institutional norm),&#xD;
             and ii. Corrected QT interval ≤450 msec e. Normal Pancreatic function defined as: i.&#xD;
             Serum amylase ≤1.5xULN and ii. Serum lipase ≤1.5xULN. f. Blood pressure within the&#xD;
             upper limit of normal defined as: i. A blood pressure (BP) ≤ 95th percentile for age,&#xD;
             height, and gender and not receiving medication for treatment of hypertension.&#xD;
&#xD;
          7. Informed Consent: All patients and/or their parents or legal guardians must sign a&#xD;
             written informed consent. Assent, when appropriate, will be obtained according to&#xD;
             institutional guidelines.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior anthracycline treatment. Patients previously treated with anthracyclines (any&#xD;
             dose) are not eligible.&#xD;
&#xD;
          2. Prior Cardiac Radiation Patients previously treated with a radiation field that&#xD;
             included the heart are not eligible.&#xD;
&#xD;
          3. Pregnancy or Breast-Feeding Animal studies indicate an increased risk of death of&#xD;
             pregnant female rats and rabbits exposed to Sutent®. Cleft lip and palate were&#xD;
             observed in some fetuses exposed in utero to sunitinib. There is yet no available&#xD;
             information regarding human fetal or teratogenic toxicities. Pregnancy tests must be&#xD;
             obtained in girls who are poet-menarchal. Males or females of reproductive potential&#xD;
             may not participate unless they have agreed to use an effective contraceptive method.&#xD;
&#xD;
          4. Concomitant Medications&#xD;
&#xD;
               1. Growth factors(s): Growth factors that support platelet or white cell number or&#xD;
                  function must not have been administered within the past 14 days&#xD;
&#xD;
               2. Investigational Drugs: Patients who are currently receiving another&#xD;
                  investigational drug.&#xD;
&#xD;
               3. Anti-cancer agents: Patients who are currently receiving other anti-cancer&#xD;
                  agents.&#xD;
&#xD;
               4. The following CYP3A4 inducers are prohibited 12 days before the start of Sutent®&#xD;
                  and during the study with Sutent®: rifampin, rifabutin, carbamazepine,&#xD;
                  Phenobarbital, phenytoin, St. John's wort, efavirenz, and tipranavir.&#xD;
&#xD;
               5. Anti-thrombotic and anti-platelet agents: warfarin (Coumadin), heparin, low&#xD;
                  molecular weight heparin, aspirin, and/or ibuprofen, or other NSAIDs.&#xD;
&#xD;
               6. The following CYP3A4 inhibitors are prohibited 7 days before the start of&#xD;
                  sunitinib and during the study with sunitinib: azole antifungals (itraconazole,&#xD;
                  ketoconazole); clarithromycin, erythromycin, diltiazem, verapamil, HIV protease&#xD;
                  inhibitors (indinavir, saquinavir, ritonavir, atazanavir, nelfinavir);&#xD;
                  delavirdine.&#xD;
&#xD;
          5. Infection: Patients who have an uncontrolled infection.&#xD;
&#xD;
          6. Pleural-based tumors: Pediatric patients treated on a phase II trial with imatinib had&#xD;
             a higher than expected rate of hemorrhagic pleural effusions. Sutent® inhibits two of&#xD;
             the same receptor tyrosine kinases as imatinib, PDGFR and c-KIT. Patients with tumors&#xD;
             involving or abutting the pleural surface will be excluded from study. Patients with&#xD;
             pulmonary lesions should be monitored closely for the development of hemorrhagic&#xD;
             pleural effusions.&#xD;
&#xD;
          7. Patient size: Due to dosing limitations, patients with body surface area &lt;0.5 m2 will&#xD;
             be excluded from study.&#xD;
&#xD;
          8. Patients with a pre-existing thyroid abnormality (hyper-or hypothyroidism) with&#xD;
             unstable thyroid function will be excluded from study. For the purposes of this study,&#xD;
             unstable thyroid function will be defined as thyroid function abnormalities requiring&#xD;
             more than on e change in thyroid medication in the 6 months prior to study entry.&#xD;
&#xD;
          9. Patients with history of allergic reaction attributed to Sutent® or component of&#xD;
             Sutent® capsules.&#xD;
&#xD;
         10. Prior use of Sutent®: Patients who have previously received sunitinib are not eligible&#xD;
             for study.&#xD;
&#xD;
         11. Patients who in the opinion of the investigator may not be able to comply with the&#xD;
             safety monitoring requirements of the study.&#xD;
&#xD;
         12. Patient is &lt; 5 years free of another primary malignancy except if the other primary&#xD;
             malignancy is not currently clinically significant nor requiring active intervention,&#xD;
             or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in&#xD;
             situ. Existence of any other malignant disease is not allowed.&#xD;
&#xD;
         13. Patient with Grade III/IV cardiac problems as defined by the New York Heart&#xD;
             Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6&#xD;
             months of study)&#xD;
&#xD;
         14. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes,&#xD;
             chronic renal disease, or active uncontrolled infection).&#xD;
&#xD;
         15. Patient has a known brain metastasis. Non-specific CNS changes on MRI/CT&#xD;
             characteristic of NF1 are allowed, but not known CNS malignancies.&#xD;
&#xD;
         16. Patient has known chronic liver disease (i.e., chronic active hepatitis, and&#xD;
             cirrhosis).&#xD;
&#xD;
         17. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         18. Patient had a major surgery within 2 weeks prior to study entry.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chie-Schin Shih, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riley Hospital for Children at IU Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <results_first_submitted>March 30, 2016</results_first_submitted>
  <results_first_submitted_qc>March 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2016</results_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Chie-Schin Shih</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>NF1</keyword>
  <keyword>plexiform neurofibromas</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Sutent®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurofibroma, Plexiform</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sutent®/Sunitinib</title>
          <description>Upon enrollment, subjects will receive Sutent® orally. Adults (Age &gt;18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg.The maximum dose for children is 15mg/m2/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Suspended by FDA</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sutent®/Sunitinib</title>
          <description>Upon enrollment, subjects will receive Sutent® orally. Adults (Age &gt;18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg.The maximum dose for children is 15mg/m2/day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Response</title>
        <description>To estimate the disease control rate (SD, PR, CR) with Sutent® in patients with neurofibromas (NF1). Tumor response criteria are determined by changes in size using all 3 dimensional measurements: width (W), transvers (T) , and length (L) measurements. Partial Response: ≥20% decrease in the sum of the products of the three perpendicular diameters of all target lesions (up to 5), taking as reference the initial baseline measurements.Stable Disease (SD): Neither sufficient decrease in the sum of the products of the three perpendicular diameters of all target lesions to qualify for PR (taking as reference the initial baseline measurements), nor sufficient increase in a single target lesions to qualify for PD, (taking as reference the smallest disease measurement since the treatment started).Progressive Disease (PD): 40% or more increase in the product of perpendicular diameters of ANY target lesion, taking as reference the smallest product observed.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sutent®/Sunitinib</title>
            <description>Upon enrollment, subjects will receive Sutent® orally. Adults (Age &gt;18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Response</title>
          <description>To estimate the disease control rate (SD, PR, CR) with Sutent® in patients with neurofibromas (NF1). Tumor response criteria are determined by changes in size using all 3 dimensional measurements: width (W), transvers (T) , and length (L) measurements. Partial Response: ≥20% decrease in the sum of the products of the three perpendicular diameters of all target lesions (up to 5), taking as reference the initial baseline measurements.Stable Disease (SD): Neither sufficient decrease in the sum of the products of the three perpendicular diameters of all target lesions to qualify for PR (taking as reference the initial baseline measurements), nor sufficient increase in a single target lesions to qualify for PD, (taking as reference the smallest disease measurement since the treatment started).Progressive Disease (PD): 40% or more increase in the product of perpendicular diameters of ANY target lesion, taking as reference the smallest product observed.</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="39.21" upper_limit="77.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volumetric Disease Evaluation</title>
        <description>To determine the response rate with Sutent® in patients with plexiform neurofibromas using volumetric analysis of MRI scans</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sutent®/Sunitinib</title>
            <description>Upon enrollment, subjects will receive Sutent® orally. Adults (Age &gt;18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg.The maximum dose for children is 15mg/m2/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Volumetric Disease Evaluation</title>
          <description>To determine the response rate with Sutent® in patients with plexiform neurofibromas using volumetric analysis of MRI scans</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the time subjects were taking drug and 30 days following completion of therapy</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sutent®/Sunitinib</title>
          <description>Upon enrollment, subjects will receive Sutent® orally. Adults (Age &gt;18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg.The maximum dose for children is 15mg/m2/day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>generalized muscle weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>blood bilirubin increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hpomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypophoshatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>serum amylase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>white blood cell decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>scoliosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cognitive disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash aceniform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chie-Schin Shih, MD</name_or_title>
      <organization>Indiana University School of Medicine - Pediatrics</organization>
      <phone>317-948-8568</phone>
      <email>shih2@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

